Data from clinical results Caris Registry presented at the ASCO annual meeting

Data from clinical results Caris Registry presented at the ASCO annual meeting -

Caris Life Sciences® and investigators Inova Fairfax Hospital presented the first clinical results Registry data presentation Caris ™ at 50 ^e annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend. These data, focusing on patients with ovarian cancer, demonstrated a significant improvement in survival in women with ovarian cancer.

"We have long speculated that customizing the selection of cancer therapy for ovarian profiling of the tumor would be beneficial to patients, and this study is a promising step forward in validating this premise for these patients, "said William McGuire, MD, Inova Fairfax Hospital.

Moreover, these data demonstrate the importance of avoiding inappropriate therapy." We found that the underlying biology is also a powerful predictor of therapies that must be avoided in ovarian cancer patients. Patients who receive cytotoxic agent when the tumor is likely to respond, experience a significant negative impact on survival, "said David Spetzler, Ph.D., vice president, research and development, Caris Life science. "As the result of a patient is strongly influenced by the ability to select appropriate therapies and avoid inappropriate therapies with improved knowledge of tumor biology underlying molecular provided by Caris Intelligence ™ Service . "

Based on a cohort of 450 patients, these data indicated that treatment consistent with the predictions of molecular profiling significantly improved overall survival in patients with ovarian, primary peritoneal carcinoma and fallopian tubes. Patients were classified according to the chemotherapeutic agents administered during their illness. Of the 450 patients, there were 278 that could be grouped into two cohorts, those whose salaries were predicted for the benefit (170) and those who received at least one treatment intended to be a lack of benefits ( 178). There were no significant differences in baseline characteristics of the two cohorts

Select highlights from this clinical trial include :.

• Patients Cohort benefits experienced significantly longer survival post-profiling, as evidenced by a reduction of 46 percent in the risk of death, compared to the lack of benefit cohort . (Relative risk = 0.54, 95 percent from 0.37 to 0.80; p = 0.0018)
• median overall survival observed for patients in the cohort of benefits (158, 0 months) compared with patients in the cohort lack of benefits (63.4 months).
• patients in the cohort benefits also followed a trend toward longer overall survival significantly, as evidenced by a reduction of 31 percent. in the risk of death, compared to no benefit cohort (hazard ratio = 0.69, 95 percent CI 0.47 to 1.02; p = 0.065)

This poster whole can be viewed at: http://www.carislifesciences.com/media/pdf/The-impact-of-tumor-molecular-profile-directed-treatment-on-survival-in-ovarian-cancer_ASCO2014-oliver-mcguire-spetzler.pdf.

"oncologists dealing with particularly complex cancers should realize the value that molecular profiling with molecular Caris intelligence can play in helping patients fight the disease as demonstrated by the data," said Caris Life Sciences Chief Medical Officer, Sandeep K. Reddy, MD

Caris Life Sciences presented an extraordinary amount of data at ASCO through oral presentation, poster highlights and posters all communications can be viewed.: http://www.carislifesciences.com/asco-2014/.